Myeloid cell activation by lipopolysaccharides (LPS) involves two proteins, plasma LPS-binding protein (LBP) and cell-membrane CD14. Cell membrane CD14, anchored by a glycerophosphatidylinositol tail, is the cellular receptor for LPS-LBP complexes. Another form of CD14, without the lipid tail, circulates as a soluble plasma protein. In this work we show that soluble CD14 (sCD14) is required for activation of endothelial and epithelial cels by LPS. We propose that LPS-LBP complexes transfer LPS to sCD14, and the LPS-sCD14 complexes then bind to a ceDlular receptor. Support for this pathway comes from experiments in which LBP and CD14 in normal human serum are blocked by specific antibodies, experiments in which serum is replaced by purified LBP and sCD14, and experiments in which specific binding of [3H]LPS to epithelial cells is quantitated.
55-kDa glycoprotein anchored to the MS membrane via a glycerophosphatidylinositol anchor (6) . The membranebound CD14 (mCD14) serves as a receptor for complexes of LPS and LBP (7) . Current evidence supports the contention that the LBP/CD14-dependent pathway contributes to MSD and granulocyte stimulation by LPS under physiologic conditions. Interestingly, a soluble form ofCD14 (sCD14) lacking the glycerophosphatidylinositol anchor is also present in serum; its origin and function have not been defined (8) .
Endothelial and epithelial cells may also play important roles in host responses to LPS during sepsis. Two distinct pathways for LPS stimulation of these cell types may occur by either direct stimulation by LPS or indirect stimulation via cytokines released from LPS-stimulated myeloid cells (9) (10) (11) (12) (13) (14) . Evidence for both pathways has been provided from in vitro studies with primary cell cultures and cell lines. Little is understood about the mechanisms that control LPS recognition and signaling by endothelial and epithelial cells. Because these cells are not known to express mCD14, there was no reason to consider that LBP and/or CD14 would be involved in regulating responses to LPS. However, LPS stimulation of endothelial cells has been reported to be enhanced by serum, and recently it has been shown that anti-CD14 monoclonal antibodies (mAbs) block effects of LPS on bovine endothelial cells cultured in the presence of serum (15) . No comparable data are available for epithelial cells.
In this report it is shown that several epithelial-like cell lines, like endothelial cells, require serum for LPS stimulation of cytokine release. Importantly, evidence is provided for a specific mechanism of LPS stimulation of endothelial and epithelial cells that involves LBP and sCD14 and provides an explanation for the serum requirement displayed by both cell types. These data suggest that LBP and sCD14 in blood or in extravascular fluids may contribute to the consequences of endotoxemia by enabling LPS preparation at 10 mg/ml from a goat anti-human recombinant LBP antiserum or with nonimmune goat IgG at 10 mg/ml as control. Precipitates were removed by centrifugation. mAb 28C5 specific for CD14 and mAbs 1E8 and 18G4 specific for LBP were isolated from hybridoma culture supernate by using the MAPS II kit (Bio-Rad); mAb IB4 specific for CD18 was from K. Arfors, La Jolla, CA. Rabbit LBP was purified from acute-phase rabbit serum (1) . Human sCD14 was immunopurified from culture supernates of CHO cells transfected with a plasmid encoding human CD14, using immobilized mAb 63D3. Human recombinant interleukin (IL)-1l3
was from J. M. Dayer, Geneva. The RPMI 1640 medium, NHS, human serum albumin (HSA; Miles), and LBP were found to be free of endotoxin by the limulus lysate assay (Whittaker Bioproducts). The sCD14 stock solution (1 mg/ ml) used had endotoxin at 5 units per ml, corresponding to S. minnesota wild-type LPS at -1 ng/ml. Cell Activation Experiments. Microtiter plates (Costar) were precoated with 0.1% gelatin (Sigma) in phosphatebuffered saline (PBS), pH 7.4 (Dulbecco's PBS; Irvine Scientific) for 15 min at room temperature. One confluent 75-cm2 flask of third-or fourth-passage HUVEC was trypsinized with 1.5 ml of trypsin-EDTA (GIBCO), seeded into three 96-well gelatin-coated plates (200 ,ul of cell suspension per well), and grown to confluency in 2-3 days. The HBEC were treated the same as the HUVEC. Individual confluent 75-cm2 flasks of SW620 cells or HT29 cells were trypsinized, as were the HUVEC, and the cells were seeded into two 96-well plates without gelatin coating, achieving confluency within 2 days. Before use, confluent cells were washed three times with RPMI 1640 medium/HSA at 1 mg/ml. Incubation of cells with LPS alone, with LPS in the presence of 2% NHS with or without additional antibodies, or with LPS in the presence of purified LBP or CD14 with or without added antibodies was done in RPMI 1640 medium plus HSA at 1, 2, or 20 mg/ml, respectively. Control experiments showed that the addition of HSA at 1, 2, or 20 mg/ml had no differential effect on the outcome of the experiment. All wells received premixed incubation medium at 200 ,l per well, were done at 37°C in 5% C02/100% humidity, and were done, at least, in triplicate. Cell viability after incubations was tested (18) .
Vascular-Cell Adhesion Molecule 1 (VCAM-1), Intercellular Adhesion Molecule 1 (ICAM-1), and Cytokine Assays. After an activation experiment culture supemates were saved at -20°C for cytokine determinations. Cellular expression of VCAM-1 and ICAM-1 was assessed with VCAM-1 or ICAM-1 mAb (R&D Systems, Minneapolis) and peroxidaseconjugated goat anti-mouse IgG (Cappel Laboratories). IL-6 and IL-8 levels were determined in supernatants from HU-VEC, HBEC, SW620, and HT29 cells using commercially available sandwich ELISA kits (R&D Systems).
Binding of [3H]LPS to SW620 Epithelial Cells. The [3H]LPS
was from R. Munford (University of Texas, Dallas) and used as described (19) . SW620 cells were grown to confluency in 6-well plates (NUNC), yielding 7-10 x 106 cells per well. The cells were washed three times with RPMI 1640 medium/HSA at 1 mg/ml at 4°C, after which they were incubated in RPMI 1640 medium/HSA at 2 mg/ml at 37°C for 1 hr, with [3H]LPS in RPMI 1640 medium/HSA at 20 mg/ml or with [3H]LPS/ RPMI 1640/2% NHS/HSA at 1 mg/ml, and with mAbs 28C5 or IB4 at 10 jig/ml. After incubation the cells were chilled to 4°C, washed once with RPMI 1640 medium/HSA at 1 mg/ml, twice with PBS, and collected for counting. Results are expressed as pg of [3H]LPS bound per well, using 5.8 x 106 dpm/,g as the specific activity. "No-cell" control wells were prepared by addition of DMEM/10% fetal bovine serum to wells for several days before treatment exactly as the experimental wells.
Cross-Linking of LPS to Serum Proteins. Re595 LPS was derivatized (20) and labeled with 1251 (21) to produce 125[-
The 125I-ASD-LPS was incubated at 500 ng/ml with NHS for 3 min at 37°C and photolysed at 253 nm for 2 min on ice. Human LBP and sCD14 were immunoprecipitated with mAb at 50 ,g/ml (1E8 and 18G4 for LBP; 63D3 and 28C5 for CD14) as first antibodies, and using a rabbit antimouse IgG at 250 ,g/ml (Zymed Laboratories) as second antibody both for 3 hr at 4°C. Labeling of purified sCD14 by 125I-ASD-LPS was studied in a 100-,ul reaction mixture by incubating 125I-ASD-LPS at 20 ng/ml with 4.5 x 10-8 M sCD14 in PBS, pH 7.4, at room temperature with or without 5 x 10-10 M purified rabbit LBP. At various times samples were withdrawn and photolysed on ice for 2 min. Labeled serum, immunoprecipitates, and proteins were analyzed by using SDS/PAGE on a 10-15% gradient gel and autoradiography. After development of the gel, labeled bands were excised to quantitate the bound 125I. RESULTS Activation of Endothelial Cells by LPS. HUVEC cultured with LPS for 6 hr in RPMI 1640 medium/HSA failed to secrete IL-8 or IL-6 and did not express ICAM-1. In contrast, HUVEC cultured with LPS/2% NHS released IL-6 and IL-8 and expressed ICAM-1 ( Fig. 1 A-C) . Serum concentrations >2% did not support higher responses, and a serum concentration of 0.03% supported only minimal responses to LPS (data not shown). Because the NHS contains LBP and sCD14, two approaches were used to determine whether these proteins mediate HUVEC stimulation by LPS. The effects of anti-CD14 or anti-LBP were examined first. When mAb 28C5, an anti-CD14, was included in the incubation with LPS/2% NHS, the ICAM-1, IL-6, and IL-8 responses were all abolished. In contrast, the addition of mAb IB4, an anti-CD18, did not change the cell responses, indicating the specificity of the anti-CD14 effect. In experiments not shown, activation of HUVEC by IL-l83 at 0.1 or 1.0 ng/ml in 2% NHS Because LBP is required for the binding of LPS to CD14 (3) immunodepletion of LBP from NHS was tested for its ability to block a HUVEC response to LPS/2% NHS.
Immunodepletion of LBP from the NHS with goat polyclonal anti-(human LBP) IgG reduced the IL-8 response nearly to that seen in the absence of NHS, whereas normal goat IgG had no effect (Fig. 1D) .
To further test the role of CD14 and LBP in responses of HUVEC to LPS, serum-free medium was reconstituted with sCD14, LBP, or both (see Fig. 2 ). As shown in Fig. 2A , VCAM-1 expression in response to LPS in serum-free medium alone is barely observable. VCAM-1 expression was not recovered with rabbit LBP at 1 ,ug/ml. However, sCD14 at 2 ,ug/ml did reconstitute the response. A mixture of rabbit LBP at 1 ,ug/ml with human sCD14 at 2 ,g/ml gave the same response as that seen with sCD14 alone (data not shown). As with the HUVEC response to LPS/2% NHS, the HUVEC response to LPS in the presence of sCD14 was abolished by mAb 28C5 but not by mAb IB4. Essentially identical results were obtained with HBEC (data not shown). The results of a more stringent examination of the requirement for LBP in this system are shown in Fig. 2 [LPS] ng/ml at 100 ng/ml and CD14 together heightened IL-8 release.
These data suggest that the presence of LBP is probably important in LPS dose ranges found during endotoxemia (22) . Activation of Epithelial Cells by LPS. To determine whether LPS stimulation of epithelial cells displayed a similar dependence upon serum, sCD14, and LBP, a human epithelial-like cell line, SW620, was used. Like HUVEC the SW620 cells release IL-8 after exposure to LPS in the presence of NHS (see Fig. 3 ). Fig. 3A shows that LPS alone is not stimulatory for these cells, but addition of 2% NHS enables a good response to LPS at as little as 100 pg/ml. As with HUVEC, anti-CD14 mAb 28C5 blocked IL-8 secretion by SW620 cells, whereas anti-CD18 mAb IB4 had no effect. In Fig. 3B , the secretion of IL-8 is seen to be blocked by immunodepletion of LBP. As shown in Fig. 3C , purified sCD14 partially enabled secretion of IL-8, whereas purified rabbit LBP only minimally enabled IL-8 secretion. However, when both CD14 and LBP were present, IL-8 was secreted at levels seen with intact 2% NHS, and this response was sensitive to anti-CD14 but was not sensitive to anti-CD18. In kinetic experiments using LPS at 0.2 ng/ml or 1 ng/ml, with CD14 and LBP, the addition of LBP ,ug/ml/anti-CD14 mAb 28C5 at 20 ,ug/ml; 9, LPS/sCD14 at 2 ,ug/ml/anti-CD18 mAb IB4 at 20 pg/ml. (B and C) Time courses of IL-8 secretion by HUVEC. Secretion stimulated with LPS at 0.15 ng/ml (B) and LPS at 0.5 ng/ml/RPMI 1640 medium (C). o, LPS alone; o, LPS/sCD14 at 100 ng/ml; A, LPS/sCD14 at 100 ng/ml/rabbit LBP at 100 ng/mI. Serum-free conditions. o, LPS/RPMI 1640 medium/HSA at 20 mg/ml; o, LPS/LBP at 1 ;kg/ml/RPMI 1640 medium; *, LPS/CD14 at 1 ,ug/ml; *, LPS/CD14 at 1 ,ug/ml/LBP at 1 ,ug/ml; *, LPS/CD14 at 1 Wg/mI/LBP at 1 ,g/ml/mAb 28C5 (anti-CD14) at 10 ,ug/ml; A, LPS/CD14 at 1 Wglml/LBP at 1 ,ug/ml/mAb IB4 (anti-CD18) at 1 ,g/ml.
were analyzed by SDS/PAGE. Fig. 5 shows that the immunoprecipitates contain radiolabeled moieties with mobilities expected for LBP and sCD14. Obviously, the nature of the cellular receptor for the CD14-LPS complexes on the endothelial and epithelial cells is of considerable interest, although not addressed by these results. That there is a specific receptor for LPS on these cells is indicated by the data showing specific binding of [3H]LPS to the SW620 cells. There is the possibility that endothelial and epithelial cells express very low levels ofmCD14 and that the mCD14 acts as the cellular receptor for sCD14-LPS complexes. If so, the mCD14 on endothelial cells and MS have different properties with regard to LBP-LPS complexes because LBP opsonizes LPS-coated particles for MF> but not for HUVEC (3) . Similarly, LBP enables M4. to respond to LPS in the absence of other proteins but does not enable either the HUVEC or SW620 cells to respond. Thus, our data suggest that the endothelial and epithelial cell receptor(s) for CD14-LPS complexes are distinct from receptor(s) for LPS-BP complexes. Note Added in Proof. A functional role for sCD14 has been proposed (27) .
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